αIIbβ3 and Its Antagonism at the New Millennium

Edward F. Plow; Czeslaw S. Cierniewski; Zihui Xiao; Thomas A. Haas; Tatiana V. Byzova

doi:10.1055/s-0037-1616198

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2001; 86(01): 34-40
DOI: 10.1055/s-0037-1616198

Research Article

Schattauer GmbH

α_IIbβ₃ and Its Antagonism at the New Millennium

Authors

Edward F. Plow

¹Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Department of Molecular Cardiology, Cleveland Clinic Foundation, Cleveland, OH, USA
Czeslaw S. Cierniewski

²Department of Biophysics, Medical University in Lodz, Lodz, Poland
Zihui Xiao

¹Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Department of Molecular Cardiology, Cleveland Clinic Foundation, Cleveland, OH, USA
Thomas A. Haas

¹Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Department of Molecular Cardiology, Cleveland Clinic Foundation, Cleveland, OH, USA
Tatiana V. Byzova

¹Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Department of Molecular Cardiology, Cleveland Clinic Foundation, Cleveland, OH, USA

Abstract

Summary

Because of its major role in regulating platelet functions and its prominence on the cell surface, integrin α_IIbβ₃ has been the subject of intensive investigations. Such studies have provided substantial insights into its structure-function relationships and have led to the development of anti-thrombotic drugs that target the receptor. Nevertheless, recent findings have indicated that our understanding of the structure and function of α_IIbβ₃ remains inadequate. This article addresses two aspects of still evolving α_IIbβ₃ function: 1) the interface between α_IIbβ₃ and the blood coagulation system, resulting from interaction of prothrombin with the receptor; and 2) the molecular basis for recognition of the RGD and the fibrinogen γ-chain peptide ligands by α_IIbβ₃. As illustrated by these two examples, there is still much to be learned about α_IIbβ₃ if we are to fully appreciate its functions and its potential as a therapeutic target.

Key words

Anti-thrombotic therapy - integrin α_IIbβ₃ - adhesive proteins - blood coagulation proteins

Full Text

References

References
1 Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999; 353: 227-31.
2 Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists – A meta-analysis of phase III multi-center randomized trials. Circulation 2001; 103: 201-6.
3 GUSTO-IV ACS Trial.. Presented at the 22nd Congress of the European Society of Cardiology. 2000 (abstr.).
4 Marguerie GA, Plow EF. The fibrinogen dependent pathway of platelet aggregation. Ann N Y Acad Sci 1983; 408: 556-67.
5 Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
6 Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem 2000; 275: 21785-8.
7 Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979; 64: 1393-401.
8 Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979; 254: 5357-63.
9 Fujimoto T, Hawiger J. Adenosine diphosphate induces binding of von Willebrand factor to human platelets. Nature 1982; 297: 154-6.
10 Ruggeri ZM, Bader R, DeMarco L. Glanzmann thrombasthenia. Deficient binding of von Willebrand factor to thrombin-stimulated platelets. Proc Natl Acad Sci USA 1982; 79: 6038-41.
11 Plow EF, Ginsberg MH. Specific and saturable binding of plasma fibronectin to thrombin-stimulated human platelets. J Biol Chem 1981; 256: 9477-82.
12 Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94: 657-66.
13 Kulkarni S, Dopheide SM, Yap CL, Ravanat C, Freund M, Mangin P, Heel KA, Street A, Harper IS, Lanza F, Jackson SP. A revised model of platelet aggregation. J Clin Invest 2000; 105: 783-91.
14 Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, Wagner DD. Persistence of platelet thrombus formation in arterioles of mice lacking both Willebrand factor and fibrinogen. J Clin Invest 2000; 106: 385-92.
15 Jedsadayanmata A, Chen CC, Kireeva ML, Lau LF, Lam SC. Activation-dependent adhesion of human platelets to Cyr61 and Fisp12/mouse connective tissue growth factor is mediated through integrin α_IIbβ₃ . J Biol Chem 1999; 274: 24321-7.
16 Felding-Habermann B, Silletti S, Mei F, Siu C-H, Yip PM, Brooks P, Cheresh DA, O’Toole TE, Ginsberg MH, Montgomery AM. A single immunoglobulin-like domain of the human neural cell adhesion molecule L1 supports adhesion by multiple vascular and platelet integrins. J Cell Biol 1997; 139: 1567-81.
17 Byzova TV, Plow EF. Networking in the hemostatic system. Integrin α_IIbβ₃ binds prothrombin and influences its activation. J Biol Chem 1997; 272: 27183-8.
18 Vijayalakshmi J, Padmanabhan KP, Mann KG, Tulinsky A. The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin. Protein Sci 1994; 3: 2254-71.
19 Stubbs MT, Bode W. A player of many parts: the spotlight falls on thrombin structure. Thromb Res 1993; 69: 1-58.
20 Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical retenosis”. J Clin Invest 1996; 98: 863-74.
21 Weiss HJ, Lages B. Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity – a comparison with Scott syndrome. Blood 1997; 89: 1599-611.
22 Bovill EG, Tracy RP, Hayes TE, Jenny RJ, Bhushan FH, Mann KG. Evidence that meizothrombin is an intermediate product in the clotting of whole blood. Arterioscler Thromb Vasc Biol 1995; 15: 754-8.
23 Byzova TV, Kim WE, Plow EF. Acceleration of prothrombin activation by its interaction with α_IIbβ₃ . Thromb Haemost. 1999 78 (suppl 1): #1301 (abstr.).
24 Clemetson KJ, Clemetson JM. Platelet GPIb-V-IX complex. Structure, function, physiology, and pathology. Semin Thromb Hemost 1995; 21: 130-6.
25 Jamieson GA, Okumura T. Reduced thrombin binding and aggregation in Bernard-Soulier platelets. J Clin Invest 1978; 61: 861-4.
26 Mazzucatto M, Marco LD, Masotti A, Pradella P, Bahou WF, Ruggeri ZM. Characterization of the initial alpha-thrombin interaction with glycoprotein Ib in relation to platelet activation. J Biol Chem 1998; 273: 1880-7.
27 Mann KG, Elion J, Butkowski RJ, Downing M, Nesheim ME. Prothrombin. Methods Enzymol 1981; 80: 286-302.
28 Moliterno DJ, Califf RM, Aguirre FV. et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Am J Cardiol 1995; 75: 559-62.
29 Furman MI, Krueger LA, Frelinger III AL, Barnard MR, Mascelli MA, Nakada MT, Michelson AD. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost 2000; 84: 492-8.
30 Kloczewiak M, Timmons S, Hawiger J. Localization of a site interacting with human platelet receptor on carboxy-terminal segment of human fibrinogen gamma chain. Biochem Biophys Res Commun 1982; 107: 181-7.
31 Gartner TK, Bennett JS. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets. J Biol Chem 1985; 260: 11891-4.
32 Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie GA, Ginsberg MH. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci USA 1985; 82: 8057-61.
33 Andrieux A, Hudry-Clergeon G, Ryckwaert J-J, Chapel A, Ginsberg MH, Plow EF, Marguerie G. Amino acid sequences in fibrinogen mediating its interaction with its platelet receptor, GPIIb-IIIa. J Biol Chem 1989; 264: 9258-65.
34 Farrell DH, Thiagarajan P, Chung DW, Davie EW. Role of fibrinogen alpha and gamma chain sites in platelet aggregation. Proc Natl Acad Sci USA 1992; 89: 10729-32.
35 Hettasch JM, Bolyard MG, Lord ST. The residues AGDV of recombinant gamma chains of human fibrinogen must be carboxy-terminal to support human platelet aggregation. Thromb Haemost 1992; 68: 701-6.
36 Rooney MM, Parise LV, Lord ST. Dissecting clot retraction and platelet aggregation. J Biol Chem 1996; 271: 8553-5.
37 Lam SCT, Plow EF, Smith MA, Andrieux A, Ryckwaert J-J, Marguerie G, Ginsberg MH. Evidence that arginine-glycine-aspartic acid and fibrinogen gamma chain peptides share a common binding site on platelets. J Biol Chem 1987; 262: 947-50.
38 Plow EF, Marguerie GA, Ginsberg M. Fibrinogen, fibrinogen receptors and the peptides that inhibit these interactions. Biochem Pharmacol 1987; 36: 4035-40.
39 Cierniewski CS, Byzova T, Papierak M, Haas TA, Niewiarowska J, Zhang L, Cieslak M, Plow EF. Peptide ligands can bind to distinct sites in integrin α_IIbβ₃ and elicit different functional responses. J Biol Chem 1999; 274: 16923-32.
40 Suehiro K, Smith JW, Plow EF. The ligand recognition specificity of β₃ integrins. J Biol Chem 1996; 271: 10365-71.
41 D’Souza SE, Ginsberg MH, Burke TA, Lam SCT, Plow EF. Localization of an Arg-Gly-Asp recognition site within an integrin adhesion receptor. Science 1988; 242: 91-3.
42 Andrieux A, Rabiet M-J, Chapel A, Concord E, Marguerie G. A highly conserved sequence of the Arg-Gly-Asp-binding domain of the integrin beta-3 subunit is sensitive to stimulation. J Biol Chem 1991; 266: 14202-7.
43 Takada Y, Puzon W. Identification of a regulatory region of integrin β₁ subunit using activating and inhibiting antibodies. J Biol Chem 1993; 268: 17597-601.
44 Alemany M, Concord E, Garin J, Vinçon M, Giles A, Marguerie G, Gulino D. Sequence 274-368 in the β₃-subunit of the integrin α_IIbβ₃ provides a ligand recognition and binding domain for the gamma-chain of fibrinogen that is independent of platelet activation. Blood 1996; 87: 592-601.
45 Loftus JC, Liddington RC. Perspectives Series: cell adhesion in vascular biology. New insights into integrin-ligand interaction. J Clin Invest 1997; 99: 2302-6.
46 Huang C, Zang Q, Takagi J, Springer TA. Structural and functional studies with antibodies to the integrin α₂ subunit. A model for the I-like domain. J Biol Chem 2000; 275: 21514-24.
47 Rahman S, Kakkar VV, Authi KS. The integrin α_IIbβ₃ contains distinct and interacting binding sites for snake-venom RGD (Arg-Gly-Asp) proteins. Evidence that the receptor-binding characteristics of snake-venom RGD proteins are related to the amino acid environment flanking the sequence RGD. Biochem J 1995; 312: 223-32.
48 Hu DD, Barbas III CF, Smith JW. An allosteric Ca²⁺ binding site on the β₃-integrins that regulates the dissociation rate for RGD ligands. J Biol Chem 1996; 271: 21745-51.
49 Emsley J, Knight CG, Farndale RW, Barnes MJ, Liddington RC. Structural basis of collagen recognition by integrin α₂β₁ . Cell 2000; 101: 47-56.